WO2025134069 - COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
National phase entry is expected:
Publication Number
WO/2025/134069
Publication Date
26.06.2025
International Application No.
PCT/IB2024/063064
International Filing Date
20.12.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
[French]
COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS
Applicants **
ARIBIO CO., LTD.
Inventors
CHOUNG, Jai Jun
Priority Data
10-2023-0190305
22.12.2023
KR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP Australia
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3381 | |
| EPO | Filing, Examination, Granting | 35106 | |
| Japan | Filing, Examination, Granting | 3359 | |
| South Korea | Filing, Examination, Granting | 4729 | |
| USA | Filing, Examination, Granting | 26540 |
Total:
73,115
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides a pharmaceutical composition comprising at least one phosphodiesterase 5 inhibitor and at least one N-methyl-D-aspartate-receptor (NMDA-receptor) antagonist, or pharmaceutically acceptable salts, solvates, or hydrates thereof. The composition is useful for treating neurodegenerative disorders. Methods of treating neurodegenerative disorders and reducing neuroinflammation by administering an effective amount of the pharmaceutical composition to a subject in need thereof are also provided. The phosphodiesterase 5 inhibitor may be mirodenafil and the NMDA-receptor antagonist may be memantine. The composition and methods result in synergistic reduction of inflammatory markers and amyloid beta levels.[French]
La présente invention concerne une composition pharmaceutique contenant au moins un inhibiteur de phosphodiestérase 5 et au moins un antagoniste du récepteur N-méthyl-D-aspartate (récepteur NMDA), ou des sels, solvates ou hydrates pharmaceutiquement acceptables de celui-ci. La composition est utile pour traiter des troubles neurodégénératifs. L'invention concerne également des méthodes de traitement de troubles neurodégénératifs et de réduction de la neuro-inflammation par administration d'une quantité efficace de la composition pharmaceutique à un sujet en ayant besoin. L'inhibiteur de phosphodiestérase 5 peut être le mirodénafil et l'antagoniste du récepteur NMDA peut être la mémantine. La composition et les méthodes conduisent à une réduction synergique de marqueurs inflammatoires et de niveaux bêta-amyloïdes.